Peter Ka FungChiu Hong Kong, China

Dr. Peter Chiu graduated from the Faculty of Medicine of the Chinese University of Hong Kong (CUHK) and obtained the fellowship in Urology from the College of Surgeons of Edinburgh. He received post-graduate training on Prostate Cancer research and Andrology in the Erasmus Medical Centre in Rotterdam, The Netherlands, and obtained a PhD degree on Prostate Cancer diagnosis. His clinical practice and research focus on Prostate cancer, from prostate cancer screening, diagnosis with novel biomarkers (prostate health index, urine spermine), MRI-guided targeted prostate biopsy, to focal therapy. He has more than 200 peer-reviewed publications to date. Dr. Chiu was involved in the development of new robotic and therapeutic devices. He is the principal investigator of the first-in-human trial of Agilis Intilume system, an endoscopic robotic system with 2 flexible arms, for transurethral bladder surgery since 2024. He was also involved in the first-in-human trials of Da Vinci SP system (2017), Targeted Microwave Ablation (TMA) (first efficacy trial, 2019), Cornerstone Robotics (CSR) (2022) and Prostate Histotripsy (2026).